CORC

在结果中检索

CORC

浏览/检索结果: 共56条，第1-10条 帮助

限定条件    
已选(0)清除 条数/页：   排序方式：
Intelligent Person Monitoring system of the UHV Power Infrastructure Line Construction site based on Deep Neural Networks 会议论文
2023-02-09至02-11
作者:  Zhu KL(朱克亮);  Shi XM(石雪梅);  Zhang TZ(张天忠);  Song HS(宋华松);  Xu JL(许金林)
收藏  |  浏览/下载：0/0  |  提交时间：2023/11/15
Multi-Object Tracking based on RGB-D Sensors 会议论文
2023-01-06至01-08
作者:  Zhu KL(朱克亮);  Shi XM(石雪梅);  Zhang TZ(张天忠);  Song HS(宋华松);  Xu JL(许金林)
收藏  |  浏览/下载：0/0  |  提交时间：2023/11/15
Ground experiment of a 50 mm balloon-borne coronagraph for near space project 会议论文
Chengdu, China, 2021-06-14
作者:  Liu Y(刘煜);  Zhang XF(张雪飞);  Song TF(宋腾飞);  Sun, Mingzhe;  Liu, Dayang
收藏  |  浏览/下载：57/0  |  提交时间：2022/03/07
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：44/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：34/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：36/0  |  提交时间：2019/12/05
THE EFFICACY AND SAFETY OF RAVIDASVIR COMBINED WITH DANOPREVIR IN THE 12-WEEK ORAL REGIMEN FOR TREATMENT-NAIVE HCV GENOTYPE 1 ADULT PATIENTS WITHOUT CIRRHOSIS IN CHINA: PHASE II/III CLINICAL TRIAL 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Zheng, Sujun;  Guan, Yujuan;  Sheng, Jifang
收藏  |  浏览/下载：32/0  |  提交时间：2019/12/05
All-oral, 12-week ravidasvir plus ritonavir-boosted danoprevir and ribavirin delivers 100% svr12 in treatment-naive non-cirrhotic hcv genotype 1 patients with resistance-associated substitutions of a phase 2/3 clinical trial in china 会议论文
作者:  Wei, Lai;  Xu, Xiaoyuan;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Ji-Fang
收藏  |  浏览/下载：29/0  |  提交时间：2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：11/0  |  提交时间：2019/12/05
Efficacy and Safety of All-Oral, 12-Week Ravidasvir Plus Ritonavir-Boosted Danoprevir and Ribavirin in Treatment-Naive Non-Cirrhotic HCV Genotype 1 Patients : Results from a Phase 2/ 3 Clinical Trial in China 会议论文
作者:  Wei, Lai;  Xu, Xiaoyun;  Guan, Yujuan;  Zheng, Sujun;  Sheng, Jifang
收藏  |  浏览/下载：11/0  |  提交时间：2019/11/19

©版权所有 ©2017 CSpace - Powered by CSpace